

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Core Lithium Ltd
ABN	80 146 287 809

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stephen BIGGINS
Date of last notice	5 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none">1. Mr Biggins is a director of and has a beneficial interest in the registered holder Nowak Investments Pty Ltd ATF The Nowak Superannuation Fund (Nowak)2. Mr Biggins is a director of and has a beneficial interest in the registered holder Genex Resources Pty Ltd ATF Biggins Resources Family Trust (Genex)
Date of change	26 November 2021

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>979,680 Shares held by Nowak</p> <p>2,226,667 Shares held by Genex</p> <p>6,500,000 Performance Rights expiring at various times to 30 June 2026 held by Genex.</p> <p>2,166,666 vested Performance Rights expiring at 30 June 2023 held by Genex.</p> <p>2,031,666 vested Performance Rights expiring at 30 June 2024 held by Genex.</p> <p>5,000,000 Options held by Genex</p>
Class	<p>Shares - Fully paid ordinary shares.</p> <p>Performance Rights – unquoted performance rights subject to satisfaction of performance conditions.</p> <p>Options - unquoted options with an exercise price of 6.0 cents each and expiry of 30 June 2023.</p>
Number acquired	750,000 Performance Rights
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$Nil
No. of securities held after change	<p>979,680 Shares held by Nowak</p> <p>2,226,667 Shares held by Genex</p> <p>7,250,000 Performance Rights expiring at various times to 30 June 2026 held by Genex.</p> <p>2,166,666 vested Performance Rights expiring at 30 June 2023 held by Genex.</p> <p>2,031,666 vested Performance Rights expiring at 30 June 2024 held by Genex.</p> <p>5,000,000 Options held by Genex</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights as approved by shareholders at the 2021 AGM.
--	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.